|EP110-C01||Pre-coated Human ACE2 Microplate||1 plate|
|EP110-C02||SARS-CoV-2 Inhibitor||10 μg|
|EP110-C03||HRP-SARS-CoV-2 Spike RBD(P.1)||15 μg|
|EP110-C04||10xWashing Buffer||50 mL|
|EP110-C05||Dilution Buffer||50 mL|
|EP110-C06||Substrate Solution||12 mL|
|EP110-C07||Stop Solution||7 mL|
Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, the deleloped of effcient treatment agaginst multiple variants of SARS-CoV-2 is an emergent need for global pubic heath.It is necessary to develop SARS-CoV-2 inhibitors, such as vaccines、therapeutic antibodies and small molecule compounds against SARS-CoV-2(P.1). Therefore, it is helpful to develop the SARS-CoV-2 (P.1) Inhibitor Screening Kit (Spike RBD) to test SARS-CoV-2 inhibitors.
This kit is developed for screening inhibitors of SARS-CoV-2(P.1).
It is for research use only.
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
This assay kit is used to measure the levels of Anti-SARS-CoV-2 neutralizing antibody through a competitive ELISA. The microplate in the kit has been pre-coated with Human ACE2 protein. First samples are added to the wells followed by addition of HRP-SARS-CoV-2 Spike RBD. After incubation, the wells are washed and substrate is added to the wells. The reaction is terminated by the addition of stop solution and the intensity of color is measured at 450 nm. The presence of neutralizing antibodies in samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The intensity of assay signal decrease proportionally to the presence of Anti-SARS-CoV-2 neutralizing antibody.
Your experiment will include 5 simple steps:
a)All reagents were returned to room temperature(20℃-25℃) before use.
b)Make series the tested sample and control with ditlution buffer,HRP-SARS-CoV-2 RBD diluted with dilution buffer.
c) Add the diluted sample ,Control and the HRP-SARS-CoV-2 RBD add the plate respectively.
d) Wash the plate and add TMB or other colorimetric HRP substrate. e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Inhibition of HRP-SARS-CoV-2 Spike RBD(P.1):SARS-CoV-2 Spike RBD Binding by SARS-CoV-2 inhibitor.
Serial dilutions of SARS-CoV-2 inhibitor (Catalog # EP110-C02) (1:1 serial dilutions, from 2.5ug/mL to 0.0049ug/mL) and loaded onto the plate coated by human ACE2 in the presence of HRP-SARS-CoV-2 Spike RBD(P.1).Background was subtracted from data points prior to log transformation and curve fitting (QC tested).